Particle Lung Interactions

This wide-ranging, comprehensive reference presents the latest developments in aerosol science and interactions between particles and the respiratory tract-utilizing an inter-disciplinary approach that integrates advances in physics, chemistry, and engineering with the epidemiological and biomedical sciences, and focusing on the dynamics of particl

Written by an expanded team of leading international scientists, the second edition thoroughly investigates research and therapies for managing adverse physiological effects of air-borne particles on the respiratory tract. The book examines the lung as the gateway for particle damage to organs outside the respiratory system and provide the information needed to understand and combat the numerous and varied ailments caused by inhaled particles.

Interactions between drug particulates are crucial in determining drug dispersion and deaggregation, and ultimately delivery efficiency. This book combines principles established in surface and colloidal chemistry with pharmaceutical powder technology. It discusses some of the factors affecting particulate interactions, and particle-fluid interaction in the respiratory tract. It review some of the studies carried out in dry powder formulation development, and proposes possible strategies in improving DPI efficiency. The majority of these principles are applicable to other pharmaceutical solid dosage forms (e.g. tablets and capsules).

This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.

"The combination of scientific and institutional integrity represented by this book is unusual. It should be a model for future endeavors to help quantify environmental risk as a basis for good decisionmaking." â€"William D. Ruckelshaus, from the foreword. This volume, prepared under the auspices of the Health Effects Institute, an independent research organization created and funded jointly by the Environmental Protection Agency and the automobile industry, brings together experts on atmospheric exposure and on the biological effects of toxic substances to examine what is knownâ€"and not knownâ€"about the human health risks of automotive emissions.

Drug therapy via inhalation route is at the cutting edge of modern drug delivery research. There has been significant progress on the understanding of drug therapy via inhalation products. However, there are still problems associated with their formulation design, including the interaction between the active pharmaceutical ingredient(s) (APIs), excipients and devices. This book seeks to cover some of the most pertinent issues and challenges of such formulation design associated with industrial production and desirable clinical outcome. The chapter topics have been selected with a view to integrating the factors that require consideration in the selection and design of device and formulation components which impact upon patient usability and clinical effectiveness. The challenges involved with the delivery of macromolecules by inhalation to both adult and pediatric patients are also covered. Written by leading international experts from both academia and industry, the book will help readers (formulation design scientists, researchers and post-graduate and specialized undergraduate students) develop a deep understanding of key aspects of inhalation formulations as well as detail ongoing challenges and advances associated with their development.

Biologic markersâ€"indicators of biological exposure or changeâ€"offer the promise of early detection of disease caused by environmental exposure. Researchers have used these markers to discover indications of pulmonary damage from low-level ozone, a finding with serious implications for health professionals and environmental regulators. Biologic Markers in Pulmonary Toxicology is a comprehensive study of this use of biologic markers. Focusing on the respiratory tract as an entryway for airborne pollutants, this volume reviews new ways of measuring markers, the need for markers to indicate dose or exposure levels, noninvasive respiratory function tests for use with healthy humans to detect sensitivity to inhaled pollutants, approaches to evaluating markers down to the cellular and biochemical levels, and more.